Literature DB >> 33917538

Epigenetics in a Spectrum of Myeloid Diseases and Its Exploitation for Therapy.

Michael Maher1, Jeannine Diesch1,2, Marguerite-Marie Le Pannérer1, Marcus Buschbeck1,2.   

Abstract

Mutations in genes encoding chromatin regulators are early events contributing to developing asymptomatic clonal hematopoiesis of indeterminate potential and its frequent progression to myeloid diseases with increasing severity. We focus on the subset of myeloid diseases encompassing myelodysplastic syndromes and their transformation to secondary acute myeloid leukemia. We introduce the major concepts of chromatin regulation that provide the basis of epigenetic regulation. In greater detail, we discuss those chromatin regulators that are frequently mutated in myelodysplastic syndromes. We discuss their role in the epigenetic regulation of normal hematopoiesis and the consequence of their mutation. Finally, we provide an update on the drugs interfering with chromatin regulation approved or in development for myelodysplastic syndromes and acute myeloid leukemia.

Entities:  

Keywords:  acute myeloid leukemia (AML); chromatin; clonal hematopoiesis of indeterminate potential (CHIP); epigenetic regulators; epigenetics; myelodysplastic syndromes (MDS); secondary acute myeloid leukemia (sAML)

Year:  2021        PMID: 33917538     DOI: 10.3390/cancers13071746

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  3 in total

1.  Vitamin C Deficiency in Patients With Acute Myeloid Leukemia.

Authors:  Tiziana Ottone; Isabella Faraoni; Giorgio Fucci; Mariadomenica Divona; Serena Travaglini; Eleonora De Bellis; Francesco Marchesi; Daniela Francesca Angelini; Raffaele Palmieri; Carmelo Gurnari; Manuela Giansanti; Anna Maria Nardozza; Federica Montesano; Emiliano Fabiani; Elisa Linnea Lindfors Rossi; Raffaella Cerretti; Laura Cicconi; Marco De Bardi; Maria Luisa Catanoso; Luca Battistini; Renato Massoud; Adriano Venditti; Maria Teresa Voso
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

2.  Divergent leukaemia subclones as cellular models for testing vulnerabilities associated with gains in chromosomes 7, 8 or 18.

Authors:  Michael Maher; Jeannine Diesch; Marguerite-Marie Le Pannérer; Marta Cabezón; Mar Mallo; Sara Vergara; Aleix Méndez López; Alba Mesa Tudel; Francesc Solé; Marc Sorigue; Lurdes Zamora; Isabel Granada; Marcus Buschbeck
Journal:  Sci Rep       Date:  2021-10-27       Impact factor: 4.379

Review 3.  Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments.

Authors:  Eric M Granowicz; Brian A Jonas
Journal:  Onco Targets Ther       Date:  2022-04-21       Impact factor: 4.345

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.